1-甲基-5-苯基-1H-吡唑-4-甲醛 | 154927-01-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基-5-苯基-1H-吡唑-4-甲醛
• 英文名称: 1-methyl-5-phenyl-1H-pyrazole-4-carbaldehyde
• 英文别名: 1-methyl-5-phenylpyrazole-4-carbaldehyde
• CAS: 154927-01-2
• 化学式: C₁₁H₁₀N₂O
• mdl: MFCD04115389
• 分子量: 186.213
• InChiKey: DLMVCAXLQMJYHP-UHFFFAOYSA-N

物化性质

• 沸点：
  356.4±30.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3 (20 ºC 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933199090

SDS

Name:	1-Methyl-5-phenyl-1H-pyrazole-4-carbaldehyde Material Safety Data Sheet
Synonym:	None Known
CAS:	154927-01-2

Section 1 - Chemical Product MSDS Name:1-Methyl-5-phenyl-1H-pyrazole-4-carbaldehyde Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
154927-01-2	1-Methyl-5-phenyl-1H-pyrazole-4-carbal	95+	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 154927-01-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: slight
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 101.5-104.5 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H10N2O
Molecular Weight: 186.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 154927-01-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Methyl-5-phenyl-1H-pyrazole-4-carbaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 6 Keep under nitrogen.
S 22 Do not breathe dust.
S 24/25 Avoid contact with skin and eyes.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 154927-01-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 154927-01-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 154927-01-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-5-苯基-1H-吡唑-4-甲醛 在 sodium hydride 作用下， 以 四氢呋喃 、 二氯甲烷 、 mineral oil 为溶剂， 反应 45.08h， 生成 3-(1-methyl-5-phenyl-1H-pyrazol-4-yl)-5-propoxy-[1,2,4]triazolo-[4,3-a]pyrazine
  参考文献：
  名称：

  基于结构的设计和并行化学在识别有效，选择性和脑渗透性磷酸二酯酶2A抑制剂中的应用。

  摘要：

  据报道，磷酸二酯酶2A（PDE2A）抑制剂在临床前认知模型中具有体内活性。为了更全面地探索PDE2A抑制的生物学特性，我们寻求鉴定与当前文献化合物相比具有增强的脑渗透性的有效PDE2A抑制剂。在应用估计的人体剂量计算的同时，利用合成化学和基于结构的药物设计，可以产生出高效，选择性，脑渗透性化合物71（PF-05085727），其对体内生化变化的影响与对PDE2A的抑制以及NMDA拮抗剂对啮齿类动物的影响的行为和电生理逆转相称。此数据支持PDE2A抑制剂增强NMDA信号的能力，以及它们对临床认知指征的进一步发展。

  DOI：

  10.1021/acs.jmedchem.7b00397
• 作为产物：
  描述：

  1 -甲基- 5 -苯基- 1H -吡唑 、 N,N-二甲基甲酰胺 在 三氯氧磷 作用下， 反应 1.0h， 以59%的产率得到1-甲基-5-苯基-1H-吡唑-4-甲醛
  参考文献：
  名称：

  基于结构的设计和并行化学在识别有效，选择性和脑渗透性磷酸二酯酶2A抑制剂中的应用。

  摘要：

  据报道，磷酸二酯酶2A（PDE2A）抑制剂在临床前认知模型中具有体内活性。为了更全面地探索PDE2A抑制的生物学特性，我们寻求鉴定与当前文献化合物相比具有增强的脑渗透性的有效PDE2A抑制剂。在应用估计的人体剂量计算的同时，利用合成化学和基于结构的药物设计，可以产生出高效，选择性，脑渗透性化合物71（PF-05085727），其对体内生化变化的影响与对PDE2A的抑制以及NMDA拮抗剂对啮齿类动物的影响的行为和电生理逆转相称。此数据支持PDE2A抑制剂增强NMDA信号的能力，以及它们对临床认知指征的进一步发展。

  DOI：

  10.1021/acs.jmedchem.7b00397

文献信息

• [EN] AGENT FOR PREVENTING OR TREATING NEUROPATHY<br/>[FR] AGENT POUR LA PRÉVENTION OU LE TRAITEMENT DE NEUROPATHIE
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2004039365A1

  公开（公告）日：2004-05-13

  The present invention provides an agent for preventing or treating neuropathy having superior action and low toxicity. This agent comprises a compound represented by the formula:wherein ring A is a 5-membered aromatic heterocycle containing 2 or more nitrogen atoms, which may further have substituent(s);B is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;X is a divalent acyclic hydrocarbon group;Z is -O-, -S-, -NR2-, -CONR2- or -NR2CO- (R2 is a hydrogen atom or an optionally substituted alkyl group);Y is a bond or a divalent acyclic hydrocarbon group;R1 is an optionally substituted cyclic group, an optionally substituted amino group or an optionally substituted acyl group, provided that when the 5-membered aromatic heterocycle represented by ring A is imidazole, then Z should not be -O-, or a salt thereof.

  本发明提供了一种具有优越作用和低毒性的预防或治疗神经病的药剂。该药剂包括一个由以下式表示的化合物：其中环A是含有2个或更多氮原子的5元芳香杂环，可能进一步具有取代基；B是一个可选择取代的碳氢基团或可选择取代的杂环基团；X是二价的无环碳氢基团；Z是-O-，-S-，-NR2-，-CONR2-或-NR2CO-（R2是氢原子或可选择取代的烷基基团）；Y是键或二价的无环碳氢基团；R1是可选择取代的环基团，可选择取代的氨基团或可选择取代的酰基团，但当环A表示的5元芳香杂环是咪唑时，Z不应为-O-，或其盐。
• HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor)
  申请人：GENESTE Herve

  公开号：US20080300260A1

  公开（公告）日：2008-12-04

  The present invention relates to heterocyclic compounds which are positive modulators of metabotropic glutamate receptor. The present invention also relates to the use of these compounds for preparing a pharmaceutical composition and to a method of treating a medical disorder, selected from neurological and psychiatric disorders associated with glutamate dysfunction.

  本发明涉及异环化合物，这些化合物是代谢型谷氨酸受体的阳性调节剂。本发明还涉及使用这些化合物制备药物组合物以及治疗神经系统和精神疾病的方法，这些疾病与谷氨酸功能障碍有关。
• Agent for preventing or treating neuropathy
  申请人：Momose Yu

  公开号：US20060004069A1

  公开（公告）日：2006-01-05

  The present invention provides an agent for preventing or treating neuropathy having superior action and low toxicity. This agent comprises a compound represented by the formula: wherein ring A is a 5-membered aromatic heterocycle containing 2 or more nitrogen atoms, which may further have substituent(s); B is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a divalent acyclic hydrocarbon group; Z is —O—, —S—, —NR 2 —, —CONR 2 — or —NR 2 CO— (R 2 is a hydrogen atom or an optionally substituted alkyl group); Y is a bond or a divalent acyclic hydrocarbon group; R 1 is an optionally substituted cyclic group, an optionally substituted amino group or an optionally substituted acyl group, provided that when the 5-membered aromatic heterocycle represented by ring A is imidazole, then Z should not be —O—, or a salt thereof.

  本发明提供了一种用于预防或治疗神经病的药剂，具有优异的作用和低毒性。该药剂包括以下式子所表示的化合物：其中环A是一个含有2个或更多氮原子的5元芳香杂环，可以进一步具有取代基；B是一个可选取代的碳氢化合物基团或可选取代的杂环基团；X是一个二价的无环碳氢基团；Z是—O—、—S—、—NR2—、—CONR2—或—NR2CO—（其中R2是氢原子或可选取代的烷基基团）；Y是一个键或一个二价的无环碳氢基团；R1是一个可选取代的环基、可选取代的氨基或可选取代的酰基，但当环A所表示的5元芳香杂环是咪唑时，Z不应为—O—，或其盐。
• Preparation of Aza-Polycyclic Aromatic Compounds via Superelectrophilic Cyclizations
  作者：Ang Li、Thomas M. Gilbert、Douglas A. Klumpp

  DOI：10.1021/jo8003474

  日期：2008.5.1

  [GRPHICS]Alkenyl-substituted N-heterocycles react in superacidic CF3SO3H (triflic acid) to produce dicationic intermediates. These superelectrophiles undergo cyclizations to give varied aza-polycyclic aromatic compounds in generally good yields (27-99%, 16 examples). Theoretical calculations indicate a preference for charge-separated dicationic intermediates.
• Charge Migration in Dicationic Electrophiles and Its Application to the Synthesis of Aza-polycyclic Aromatic Compounds
  作者：Ang Li、Patrick J. Kindelin、Douglas A. Klumpp

  DOI：10.1021/ol060125u

  日期：2006.3.1

  Superacid-promoted reactions of dicationic electrophiles have been studied, and the positive charge centers are found to migrate apart in a predictable manner. Using isotopic labeling the charge migration is found in one system to occur through successive deprotonation-reprotonation steps. The charge migration chemistry is the basis for new general synthetic route to aza-polycyclic aromatic compounds.